Back to Search Start Over

Glabellar Lines Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Revance Therapeutics, ATGC Biotech, AbbVie, Ipsen, Eirion

Source :
M2 Presswire. November 8, 2023
Publication Year :
2023

Abstract

M2 PRESSWIRE-November 8, 2023-: Glabellar Lines Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Revance Therapeutics, ATGC Biotech, AbbVie, Ipsen, Eirion (C)1994-2023 [...]

Subjects

Subjects :
Business -- Research
Biotechnology -- Reports -- Forecasts and trends
Biotechnology industry -- Forecasts and trends -- Product development
Clinical trials -- Forecasts and trends -- Reports
Market trend/market analysis
Business
Business, international

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Presswire
Publication Type :
News
Accession number :
edsgcl.771930767

Tools

Authors Abstract Subjects Details